Evotec extends collaboration with CHDI Foundation
Partnership aims to accelerate development of drugs that slow progression of Huntington’s disease
The CHDI Foundation, a privately funded not-for-profit research organisation in the US dedicated to developing treatments for Huntington’s disease (HD), has extended its collaboration with Evotec until the end of 2015. Evotec, which is based in Hamburg, Germany, could be entitled to research payments worth up to US$41m with this contract extension.
The collaboration takes advantage of Evotec's integrated drug discovery platform and its proficiency in neurological research, including its expertise in medicinal chemistry, in vitro and in vivo pharmacology and compound management.
Evotec and CHDI entered into this alliance in March 2006, and since then the relationship has grown significantly.
Dr Mario Polywka, chief operating officer of Evotec, said: ‘This collaboration is an excellent example of how companies, including foundations such as CHDI, can access Evotec’s platform suite of technologies, capabilities and strong disease biology expertise, to drive their drug discovery efforts.’
Dr Robert Pacifici, chief scientific officer at CHDI, said: ‘Evotec represents one of our largest and longest standing relationships with a contract research organisation. We are delighted that, with the renewal of our contract, CHDI and Evotec will be able to continue our productive interactions and drive our therapeutic programmes forward.’
